News
-
Respira Therapeutics has announced the initiation of a Phase 2b trial of its RT234 dry powder vardenafil in patients with pulmonary arterial hypertension (PAH). The open label study will include two cohorts, with the first receiving a… Read more . . .
-
CDMO Lonza has joined the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS), the company said. In the announcement of its IPAC-RS membership, Lonza specifically noted its planned participation in discussions related to particle… Read more . . .
-
Revelation Biosciences has announced that a Phase 2b viral challenge study of its REVTx-99a intranasal phosphorylated hexaacylated disaccharide (PHAD) for the prevention of H3N2 influenza in healthy volunteers failed to meet its primary endpoint. The… Read more . . .
-
Koura has officially opened a new facility for the production of HFA 152a in Runcorn, UK, the company announced. According to Koura, the propellant produced at the facility, which will be marketed as “Zephex 152a,”… Read more . . .
-
Proveris Scientific has announced the launch of a new collection system called Kinaero Cx that is designed for improved sample collection consistency during MDI testing. The new system, which includes the company’s Vereo automated actuator technology,… Read more . . .
-
The Indian Ministry of Science & Technology’s Technology Development Board (TDB) has signed a development and commercialization agreement with Hyderabad-based Sapigen Biologix, committing ₹100 crores to development of a novel intranasal vaccine against COVID-19 and… Read more . . .
-
CyanVac subsidiary Blue Lake Biotechnology is planning a Phase 1 trial of its BLB-201 intranasal vaccine against respiratory syncytial virus (RSV) after receiving FDA clearance for its IND, CyanVac said. The Phase 1 trial will… Read more . . .
-
OxyContin maker Purdue Pharma will provide an additional $11 million to non-profit Harm Reduction Therapeutics (HRT) for continued development of HRT’s HRT001 naloxone nasal spray for the reversal of opioid overdose. The additional funding was… Read more . . .
-
Virpax has announced an expansion of its license agreement with Nanomerics to add worldwide rights to AnQlar nasal spray, an antiviral mucoadhesive polymer derived from chitosan. The original license agreement, which was announced in August… Read more . . .
-
Inhaled lactose manufacturer DFE Pharma, API manufacturer Sterling, and filling/packaging company Harro Höfliger have partnered to create an early development service for DPIs called “INTO” (Inhalation Together). According to the INTO web site, the partnership… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland